Goods & Services

Active chemical ingredients for use in the manufacture of pharmaceuticals for treating cancer and inflammatory conditions Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer and inflammatory conditions Medical apparatus for facilitating the inhalation of pharmaceutical preparations; Medical apparatus for introducing pharmaceutical preparations into the human body

Abstract

The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier.

IPC Classes  ?

• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61P 35/00 - Antineoplastic agents
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 31/415 - 1,2-Diazoles
• A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)

Abstract

The present application presents compositions and methods for the intranasal administration of perillyl alcohol and L-Dopa to a patient in need of treatment for Parkinson's Disease. The compositions and methods of the present application enhance the entry of L-Dopa into the brain of the patient suffering from Parkinson's Disease

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
• A61K 31/05 - Phenols
• A61K 31/133 - Amines, e.g. amantadine having hydroxy groups, e.g. sphingosine

Abstract

The present invention provides a method for treating inflammation in a mammal. The method includes delivering to the mammal a therapeutically effective amount of a composition including a perillyl alcohol (POH) conjugated with linoleic acid. The present invention also provides a method for treating or preventing damage from UV exposure in a mammal.

IPC Classes  ?

• A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiationTopical sun tanning preparations
• A61K 31/231 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds

Abstract

The present invention provides an intranasal glioblastoma therapy with purified perillyl alcohol. Patients with recurrent glioblastoma when treated with perillyl alcohol purified by tge disclosed methods showed improved survival when compared to historical controls. Glioblastoma patients with an isocitrate dehydrogenase 1 (IDH1)-mutation showed improved survival when compared with wild-type IDH patients.

IPC Classes  ?

• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
• A61N 5/00 - Radiation therapy
• C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier.

IPC Classes  ?

• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The disclosure relates to compositions, methods, and kits for using perillyl alcohol and/or an Argonaute protein (e.g., Ago-2) to deliver a polynucleotide to a cell. The disclosure also relates to compositions, methods, and kits for treating a condition by using perillyl alcohol and/or an Argonaute protein (e.g., Ago-2) to deliver a polynucleotide to a cell. The conditions may be brain vascular diseases and brain tumors.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/05 - Phenols
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as a primary cutaneous lymphoma which may be a cutaneous T cell lymphoma (CTCL). The CTCL may be mycosis fungoides, primary cutaneous anaplastic large cell lymphoma (ALCL), or Sezary syndrome. A patient may be administered a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene).

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 15/117 - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs

Goods & Services

Active chemical ingredients for use in the manufacture of pharmaceuticals for treating cancer Pharmaceutical products for the treatment of cancer

Abstract

The present invention provides a method for treating inflammation in a mammal. The method includes delivering to the mammal a therapeutically effective amount of a composition including a perillyl alcohol (POH) conjugated with linoleic acid.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier.

IPC Classes  ?

• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07C 13/23 - Monocyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with a six-membered ring with a cyclohexadiene ring

Abstract

The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of a perillyl alcohol derivative such as a perillyl alcohol ester, or an isoperillyl alcohol derivative such as an isoperillyl alcohol ester. The derivative may be a perillyl alcohol or an isoperillyl alcohol conjugated with a therapeutic agent such as valproic acid. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

IPC Classes  ?

• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate

Abstract

NEO218 (3-bromo-2-oxo-propionic acid 4-isopropenyl-cyclohex-l-enylmethyI ester), (see formula I), is a novel molecule that was generated by covalent fusion of two unrelated agents: 3- bromopyruvate (3-BF; an alkylating agent that Inhibits cancer cell metabolism) and perillyi alcohol (POH; a natural monoterpene with anticancer properties ). Methods of synthesizing NBO218, pharmaceutical compositions comprising NBO218 and methods of treating cancer using NBO218 are also disclosed.

IPC Classes  ?

• A01N 43/52 - 1,3-DiazolesHydrogenated 1,3-diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/05 - Phenols
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine

Abstract

The present methods treat neurofibromatosis by a administering to a subject perillyl alcohol or iso-perillyl alcohol. The present methods also treat neurofibromatosis by administering to a subject a carbamate of perillyl alcohol, or a carbamate of iso-perillyl alcohol. The perillyl alcohol carbamate may comprise perillyl alcohol conjugated with rolipram or temozolomide.

IPC Classes  ?

• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine

Abstract

A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.

IPC Classes  ?

• A01N 43/38 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Abstract

The present invention provides for a perillyl alcohol (POH) carbamate, such as POH-Rolipram. The present invention also provides for a method of treating a disease such as cancer, by delivering to a patient a therapeutically effective amount of POH-Rolipram. The present invention provides for a pharmaceutical composition comprising a perillyl alcohol carbamate. The perillyl alcohol carbamate may be perillyl alcohol conjugated with a therapeutic agent, such as a chemotherapeutic agent. The chemotherapeutic agent may be rolipram. In one embodiment, the perillyl alcohol carbamate may 4-(3-cyclopentyloxy-4- methoxy phenyl)-2-oxo-pyrrolidine-1-carboxylic acid 4-isopropenyl cyclohex- 1 -enylmethyl ester (POH-Rolipram).

IPC Classes  ?

• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

Abstract

A method of treating nasopharyngeal carcinoma in a mammal includes delivering to the mammal a therapeutically effective amount of a perillyl alcohol (POH) carbamate which is a perillyl alcohol conjugated with temozolomide (TMZ).

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

A method for treating brain metastases of a cancer in a mammal includes administering to the mammal a therapeutically effective amount of a perillyl alcohol carbamate, such as TMZ-POH. The brain metastases can be originated or spread from breast cancer. The penllyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent, such as a chemotherapeutic agent. The chemotherapeutic agents that may be used in the present invention include a DNA alkylating agent, a topoisomerase inhibitor, an endoplasmic reticulum stress inducing agent, a platinum compound, an antimetabolite, an enzyme inhibitor, and a receptor antagonist.

IPC Classes  ?

• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine

Goods & Services

Active chemical ingredients for use in the manufacture of pharmaceuticals for treating cancer. Pharmaceutical products for the prevention and treatment of cancer; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer. Medical apparatus for facilitating the inhalation of pharmaceutical preparations; medical apparatus for introducing pharmaceutical preparations into the human body.

Abstract

The present invention, provides for a deuterium-enriched monoterpene or sesquiterpene such as perillyl alcohol, or a deuterium-enriched isomer or analog of monoterpenes or sesquiterpenes, such as isoperillyl alcohol. The present invention also provides for a deuterium-enriched derivative of a monoterpene or sesquiterpene, such as a perillyl alcohol carbamate, or a deuterium-enriched derivative of an isomer or analog of a monoterpene or sesquiterpene, such as an isoperillyl alcohol carbamate. The deuterium-enriched derivative may be perillyl alcohol or isoperillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a deuterium-enriched compound.

IPC Classes  ?

• C07C 35/18 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing six-membered rings with unsaturation at least in the ring

Abstract

The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

IPC Classes  ?

• C07C 35/18 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing six-membered rings with unsaturation at least in the ring

Abstract

The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w) The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w) The purified monoterpene can be used to treat a disease such as cancer The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

IPC Classes  ?

• A01N 43/78 - 1,3-ThiazolesHydrogenated 1,3-thiazoles